BiomX News

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. Calidi Biotherapeutics (AME

BenzingaJun 4 16:31 ET

BiomX Faces NYSE Delisting Over Equity Deficiency

TipRanksMay 30 18:03 ET

Express News | BiomX Receives Notice Of Non-Compliance With NYSE American Listing Standards

BenzingaMay 30 16:51 ET

Express News | Biomx Inc. Receives Notice of Non-Compliance With NYSE American Continued Listing Standards

ReutersMay 30 16:50 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersMyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (N

BenzingaMay 30 16:31 ET

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target

GlobeNewswireMay 30 07:00 ET

BiomX Initiated at Buy by Laidlaw & Co.

BiomX Initiated at Buy by Laidlaw & Co.

Dow JonesMay 28 11:45 ET

Express News | Laidlaw & Co. Initiates Coverage On BiomX With Buy Rating, Announces Price Target of $2.5

BenzingaMay 28 11:36 ET

Ladenburg Thalmann Maintains BiomX(PHGE.US) With Buy Rating, Cuts Target Price to $2

Ladenburg Thalmann analyst Michael Higgins maintains $BiomX(PHGE.US)$ with a buy rating, and adjusts the target price from $4 to $2.According to TipRanks data, the analyst has a success rate of 34.1%

moomoo NewsMay 23 08:33 ET

BiomX Buy Rating Affirmed on Clinical Progress and Strategic Acquisition

TipRanksMay 22 06:46 ET

Q1 2024 Biomx Inc Earnings Call

Yahoo FinanceMay 22 00:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target

BenzingaMay 21 11:38 ET

BiomX Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 488.58% HC Wainwright & Co. → $2 Reiterates Buy → Buy 04/22/2024 488.58% HC Wainwright & Co. →

BenzingaMay 21 11:37 ET

BiomX's Strategic Progress and Positive Trials Fuel Buy Rating

TipRanksMay 21 10:55 ET

Earnings Call Summary | BiomX(PHGE.US) Q1 2024 Earnings Conference

The following is a summary of the BiomX (PHGE) Q1 2024 Earnings Call Transcript:Financial Performance:BiomX reported a cash balance and short-term deposits of $44.1 million as of March 31, 2024, a sig

moomoo AIMay 21 10:42 ET · Conference Call

BiomX (PHGE) Q1 2024 Earnings Call Transcript

BiomX (PHGE) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 21 10:25 ET

Express News | BiomX Q1 EPS $(0.28) Down From $(0.20) YoY, With Cash Balance Of $44.1M Expected To Provide Cash Runway Into Q4 Of 2025

BenzingaMay 21 06:37 ET

Express News | Biomx Inc: Cash, Cash Equivalents and Short-Term Deposits Sufficient to Fund Its Operations Through Q4 2025.

ReutersMay 21 06:32 ET

BiomX: Cash Balance, Short-Term Deposits and Restricted Cash as of March 31, $44.1M >PHGE

BiomX: Cash Balance, Short-Term Deposits and Restricted Cash as of March 31, $44.1M >PHGE

Dow JonesMay 21 06:32 ET

BiomX 1Q EPS 28c >PHGE

BiomX 1Q EPS 28c >PHGE

Dow JonesMay 21 06:31 ET